USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Bearsden Bio, Inc.
Address:
34 MT PLEASANT DR
Frazer, PA 19014
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $494,122.00 5
SBIR Phase II $1,555,917.00 2

Award List:

NOVEL TARGETS FOR CONTROL OF APP EXPRESSION

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$99,769.00
Agency:
HHS
Principal Investigator:
Giordano, anthony
Abstract:
Alzheimer's disease is a major illness affecting an increasingly larger percentage of the population. As yet, the cause of the disease remains unknown, complicating the development of effective therapeutics. However, evidence continues to implicate the Abeta peptide, derived from the APP protein,… More

POSTTRANSCRIPTIONAL CONTROL OF IGF I RECEPTOR EXPRESSION

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Temeles, gretchen l
Abstract:
Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer death for men in the United States. Prostate tumor cells express high levels of the IGF-I receptor (IGF-IR) and because bone marrow is rich in the ligands, IGF-I and IGF-II, it has been proposed that a… More

AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EPILEPSY

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$95,231.00
Agency:
HHS
Principal Investigator:
Sturgess, michael a
Abstract:
The development of novel compounds that regulate specific subtypes of glutamate receptors for the treatment of CNS disorders is the major goal of Symphony Pharmaceuticals, Inc. Symphony discovered a novel series of heterocyclic 1,2-dihydrophthalazines that selectively antagonize AMPA receptors and… More

MOLECULAR CLONING OF UNIQUE CYTOKINES & PROTOONCOGENES

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Giordano, anthony
Abstract:
N/a

Kainate Receptor Antagonists to Treat Neuropathis Pain

Award Year / Program / Phase:
1998 / SBIR / Phase II
Award Amount:
$744,554.00
Agency:
HHS
Principal Investigator:
Sturgess, michael a
Abstract:
The development of novel compounds that regulate specific subtypes of glutamate receptors for the treatment of CNS disorders is the major goal of Symphony Pharmaceuticals, Inc. Symphony discovered a novel series of heterocyclic 1,2-dihydrophthalazines that selectively antagonize AMPA receptors and… More

SITE DIRECTED PROTEIN ANALYSIS WITH NOVEL AMINO ACIDS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$99,122.00
Agency:
HHS
Principal Investigator:
Karginov, Vladimir
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase II
Award Amount:
$811,363.00
Agency:
HHS
Principal Investigator:
Karginov Vladimir
Abstract:
N/a